GLP-1 weight loss variation explained: what TikTok gets right and wrong

What did @jory37607 actually say?

Honestly, this one is tricky to assess. The transcript provided, which is what @jory37607 actually said on camera, is incoherent. It reads like song lyrics or a TikTok audio overlay: "Cause I make it so easy I walk in Central Park I could be fresh air." None of the substantive claims in the caption, about starting weight, dose ranges like "0.25mg vs 2.4mg," sleep, stress, or TikTok's survivorship bias, appear to have been spoken aloud in the video.

So the claims we are fact-checking come from the caption, not the creator's mouth. That distinction matters. A caption is easier to revise and less likely to be the thing a viewer actually absorbs. What viewers heard was a pop audio clip. What they may have read, if they paused to look, was a more nuanced explanation of GLP-1 variability.

With that caveat on the table, the caption claims are worth examining on their merits, because they reflect a common narrative circulating in the GLP-1 community.

Does the science back this up?

Yes, more than you might expect. The caption's core argument, that GLP-1 outcomes vary because of dose, starting weight, diet, sleep, and stress, is broadly consistent with the clinical literature. This is not a bold or controversial take. It is, in fact, fairly well established.

On dose: the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced around 20.9% mean body weight reduction, compared to roughly 14.7% at 5mg. Dose is not a minor variable. On starting weight: people with higher baseline BMI tend to lose more absolute weight, but not always more percentage weight. On sleep: Nedeltcheva et al. (2010, Annals of Internal Medicine) demonstrated that sleep restriction meaningfully reduces fat loss even under caloric restriction. On stress: elevated cortisol is linked to blunted weight loss response across multiple metabolic studies. The caption did not make anything up here.

What did they get wrong (or right)?

The caption got the broad strokes right. The point about TikTok showing "the wins, not the plateaus or frustrating weeks" is genuinely useful. Survivorship bias in social media weight loss content is a documented problem, not just a vibe. People post transformations, not stalls.

Where the caption is imprecise is the dose framing. Citing "0.25mg vs 2.4mg" without naming the drug creates confusion. Those figures correspond to semaglutide's starting dose and its maximum approved dose for weight management (Wegovy), respectively. Tirzepatide uses entirely different dosing increments. Mixing them without clarity could mislead viewers who are on a different medication entirely.

There is also no mention of genetic factors, which are increasingly recognised as relevant. A 2023 study by Lotta et al. in Nature Medicine identified genetic variants associated with differential GLP-1 receptor response. That omission does not make the caption wrong, but it makes it incomplete.

What should you actually know?

If you are on a GLP-1 medication and your results differ from someone else's, the caption's explanation is a reasonable starting framework, just not the complete picture.

• Dose matters significantly. Trials consistently show dose-dependent weight loss with both semaglutide and tirzepatide.
• Sleep deprivation actively undermines fat loss, even on medication. Nedeltcheva et al. (2010) found participants lost 55% less fat when sleep-restricted.
• Stress and cortisol are not just lifestyle noise. They have measurable effects on metabolic rate and fat distribution.
• TikTok's algorithm amplifies outlier success stories. The median result in clinical trials is not a three-stone loss in 12 weeks. SURMOUNT-1's dramatic results occurred over 72 weeks, not 12.
• If your progress feels slow, that is not evidence the medication is failing. Plateaus are documented in every major GLP-1 trial.

Talk to a regulated prescriber about your specific dose, timeline, and any factors that might be affecting your response. Do not adjust doses based on what someone else is taking, regardless of their results.